Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Goodwill (2021 - 2024)

Historic Goodwill for Barinthus Biotherapeutics (BRNS) over the last 4 years, with Q3 2024 value amounting to $12.2 million.

  • Barinthus Biotherapeutics' Goodwill changed 0.0% to $12.2 million in Q3 2024 from the same period last year, while for Sep 2024 it was $12.2 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $12.2 million for FY2023, which is 0.0% changed from last year.
  • Latest data reveals that Barinthus Biotherapeutics reported Goodwill of $12.2 million as of Q3 2024, which was down 0.0% from $12.2 million recorded in Q2 2024.
  • Over the past 5 years, Barinthus Biotherapeutics' Goodwill peaked at $12.6 million during Q4 2021, and registered a low of $12.2 million during Q4 2022.
  • Over the past 4 years, Barinthus Biotherapeutics' median Goodwill value was $12.2 million (recorded in 2022), while the average stood at $12.3 million.
  • Per our database at Business Quant, Barinthus Biotherapeutics' Goodwill plummeted by 333.33% in 2022 and then changed by 0.0% in 2023.
  • Barinthus Biotherapeutics' Goodwill (Quarter) stood at $12.6 million in 2021, then decreased by 3.33% to $12.2 million in 2022, then changed by 0.0% to $12.2 million in 2023, then changed by 0.0% to $12.2 million in 2024.
  • Its Goodwill was $12.2 million in Q3 2024, compared to $12.2 million in Q2 2024 and $12.2 million in Q1 2024.